BREATHTEK UBT KIT

MAUDE Adverse Event Report

MAUDE data represents reports of adverse events involving medical devices. This maude entry was filed from a health professional report with the FDA on 2017-06-02 for BREATHTEK UBT KIT manufactured by Otsuka Pharmaceuticals.

Event Text Entries

[76509014] On 08-mar-2011, a male consumer reported that after taking pranactin-citric solution of an unknown amount he experienced burning feet and hand syndrome. The patient did not indicate whether he had sought medical assistance. Follow up received: in a follow up email on 22-mar-2011, the patient continued to experience burning pain and discomfort. Follow-up received: on 25-mar-2011, the consumer reported that he took the breathtek test around (b)(6) 2011. He retook the test around (b)(6) 2011. Two weeks later, around (b)(6) 2011, the consumer experienced a burning sensation on his palms and soles that progressed to achy leg muscles which made it painful to sit. He stated that his legs worsened throughout the course of the day and felt better when laying down. He noted that his hands and arms were sensitive to heat. He stated that his discomfort level was at an 8 out of 10 at the beginning but was at a 4 out of 10 at the time of reporting. The consumer visited his primary healthcare professional and an endocrinologist. The results of a blood test were normal with no elevated liver tests or vitamin deficiencies. Corrective treatment included gabapentin 300 mg. Follow-up received: the consumer stated that there had been no improvement in symptoms. The consumer was still experiencing leg pain. Despite having several tests done, the consumer's physician has been unable to diagnose what is the cause of the pain. Follow-up received: the consumer stated that at the time of this follow up there was no diagnosis. The consumer confirmed that an echocardiogram, electromyogram, magnetic resonance imaging scan, and an ultrasound of the legs were done and the results were normal. The consumer is still experiencing severe pain in both legs when standing or sitting. The consumer stated that the pain diminishes if he lays down and raises his legs above the heart. The consume is taking tramadol 50 mg for the pain. He states that without the pain medicine the blood pressure in his leg reaches 170/90 mmhg, increasing with the level of pain. Laboratory results show a low red blood cell count and high cholesterol. Follow-up information received on 07-jul-2015 from fda: (b)(6). Per the additional information received on 07-jul-2015, the patient has not recovered from the burning hand and feet syndrome. The clinical outcome for the achy leg muscles and painful to sit was unknown. Reviewed new information from fda letter dated june 11, 2015: the event outcome is recorded as disability or permanent damage, and the event has not resolved. The case was upgraded to serious due to these reasons. No other new medical information received. The case has limited information and further information is needed regarding patient's medical records, concomitant medications, investigation reports in order to perform a complete medical assessment. In reviewing the previous communications physician contact information was not provided which will be requested again. In view of the limited information and lack of alternative explanation the company assessment is events are related to breathtek. Closed pqc investigation report was received on 12-may-2017: all the batch records for the potential pranactin bulk lot numbers were re-reviewed and no deviations or anomalies were noted for all the batches. Based on the investigation results it is determined that the potential pranactin citric bulk and pouched lots involved in this complaint have no manufacturing or quality related issues that could have contributed to the adverse event complaint. Based on the product quality complaint investigation results, the root cause of the complaint is "undetermined" and based on investigation there is no device malfunction. Otsuka causality assessment: the case has limited information and further information is needed regarding patient's medical records, concomitant medications, investigation reports in order to perform a complete medical assessment. Although limited information is available, the reported events were considered as related to breathtek, given the temporal association, and lack of alternative explanation for the reported events. Based on the pqc results, the root cause of the complaint was "undetermined" and there was no device malfunction.
Patient Sequence No: 1, Text Type: D, B5


MAUDE Entry Details

Report Number3000718406-2017-00002
MDR Report Key6607558
Report SourceHEALTH PROFESSIONAL
Date Received2017-06-02
Date of Report2017-05-31
Date of Event2011-01-28
Date Mfgr Received2017-05-12
Date Added to Maude2017-06-02
Event Key0
Report Source CodeManufacturer report
Manufacturer LinkY
Number of Patients in Event0
Adverse Event Flag3
Product Problem Flag3
Reprocessed and Reused Flag3
Health Professional0
Initial Report to FDA0
Report to FDA3
Event Location3
Manufacturer ContactDR MIRZA RAHMAN
Manufacturer Street508 CARNEGIE CENTER DR
Manufacturer CityPRINCETON NJ 08540
Manufacturer CountryUS
Manufacturer Postal08540
Single Use3
Previous Use Code3
Event Type3
Type of Report3

Device Details

Brand NameBREATHTEK UBT KIT
Generic NameUREA BREATH TEST (UBT) AND CALCULATION SOFTWARE
Product CodeMSQ
Date Received2017-06-02
OperatorHEALTH PROFESSIONAL
Device AvailabilityN
Device Eval'ed by MfgrR
Device Sequence No1
Device Event Key0
ManufacturerOTSUKA PHARMACEUTICALS
Manufacturer Address508 CARNEGIE CENTER DR PRINCETON NJ 08540 US 08540


Patients

Patient NumberTreatmentOutcomeDate
101. Deathisabilit 2017-06-02

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.